Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Nasdaq

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

    The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    - PMLiVE

    AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn

    The companies will aim to develop tumour-activated immunotherapies, including masked T-cell engagers

    - PMLiVE

    Researchers develop immunotherapy to prevent prostate cancer treatment resistance

    The second-most common cancer in the UK affects more than 52,000 men every year

    - PMLiVE

    Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

    The formulation reduces treatment time by around 80% compared to intravenous infusion

    - PMLiVE

    Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

    The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

    - PMLiVE

    MIT study reveals why certain immunotherapies do not always work

    The findings could help doctors determine which drugs would benefit patients most

    - PMLiVE

    US study finds potential new way of improving immunotherapy for tumours

    ‘Warming up’ cold tumours assisted immunotherapy in tackling tumours

    - PMLiVE

    Takeda and F-star announce immunotherapy partnership worth over $1bn

    Both companies will research and develop antibodies for new immuno-oncology targets

    - PMLiVE

    Sanofi and Innate Pharma expand cancer therapeutics collaboration

    The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

    - PMLiVE

    The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment

    Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?

    Say Communications

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links